Anderson Clinical Research

Redlands, California 92374

3 studies enrolling now · 48 studies all time

What they study most

Alzheimer Disease, Alzheimer Disease (AD), Alzheimer's Disease, Chronic Migraine, Depression, Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant, Episodic Migraine, Generalized Anxiety Disorder, Major Depressive Disorder, Migraine, Migraine Disorders

Studies at this site

• Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms — Recruiting now
• A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — Recruiting now
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease — Recruiting now
• A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder — Running, not enrolling
• A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) — Completed
• A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder — Completed
• Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD) — Completed
• Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder — Stopped early
• A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder — Completed
• A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) — Running, not enrolling
• Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression — Completed
• Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder — Completed
• A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder — Completed
• ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder — Completed
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy — Completed
• A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy — Completed
• A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression — Completed
• A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease — Stopped early
• A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 — Stopped early
• Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention — Stopped early
• Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults — Completed
• Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION) — Completed
• A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine — Completed
• A Study of LY3437943 in Participants With Type 2 Diabetes — Completed
• A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease — Completed
• Evaluation of Galcanezumab in the Prevention of Chronic Migraine — Completed
• Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLS — Completed
• 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease — Stopped early
• A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine — Completed
• SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study — Stopped early
• Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder — Completed
• Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD) — Completed
• BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease. — Completed
• An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine — Completed
• Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder — Completed
• Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study — Completed
• A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder — Completed
• A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01) — Completed
• Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo — Stopped early
• Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine — Completed
• Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder — Completed
• Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease — Completed
• Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression — Completed
• Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression — Stopped early
• Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 — Completed
• Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder — Completed
• Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type — Completed